Skip to content

Association of platelet function with coronary blood flow and myocardial perfusion in NSTE-ACS patients receiving PCI

Association of platelet function with coronary blood flow and myocardial perfusion in NSTE-ACS patients receiving PCI

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053402
Enrollment
Unknown
Registered
2021-11-20
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

case series:Nil

Sponsors

Shanghai Chest Hospital, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged >= 18 years; 2. Diagnosed as NSTE-ACS with at least two of the following:symptoms of myocardial ischemia;abnormal ST segment (depression or transient elevation >= 0.1mv) or T wave inversion on the ECG (>= 2 relevant leads); elevated cTn; 3. Patients with intermediate or high risk: complicated with diabetes, renal insufficiency (eGFR 109; 4. Plan to undergo PCI (intervention time point according to the doctor's judgment), and plan to use aspirin and a P2Y12 receptor inhibitor for at least one year after surgery; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Female patients who are breastfeeding or who may be pregnant; 2. Patients with stable coronary heart disease; 3. Interventional surgery should be performed more than 96 hours after symptoms appear; 4. STEMI patients or STEMI before intervention; 5. The patient plans to undergo CABG; 6. The patient is unable or refuses to undergo PCI; 7. The patient has bleeding tendency, active bleeding, coagulation dysfunction or blood system disease; 8. The patient has been taking any P2Y12 receptor inhibitor for a long time; 9. The patient takes anticoagulation therapy for a long time; 10. The patient has used any thrombolytic therapy since the onset of the disease; 11. The patient has contraindications to taking aspirin or P2Y12 receptor inhibitors; 12. The patient has malignant tumor and/or life expectancy is less than 1 year; 13. During the study period, the patient wishes to discontinue participation.

Design outcomes

Primary

MeasureTime frame
Platelet function;Myocardial perfusion;

Countries

China

Contacts

Public ContactShen Linghong

Shanghai Chest Hospital

rjshenlinghong@126.com+86 13916495713

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026